title: Primary pleural of mucosa-associated lymphoid tissue lymphoma.
abstract: A 68-year-old female presented with shortness of breath. Chest radiography showed pleural effusion in the right side only. She was suspected of having ovarian cancer because CA125 levels were increased in the pleural effusion, and she consulted our hospital. A chest CT scan showed right pleural nodular lesions. Thoracoscopic pleural resection was performed. Histologic examination of a biopsy specimen showed the diffuse infiltration of small∼medium, mature lymphocytes. These lymphocytes were found to be positive for CD20 and CD79a, but negative for CD3 by immunohistochemistry. These results were interpreted as being consistent with a diagnosis of mucosa-associated lymphoid tissue lymphoma (MALT lymphoma). She commenced chemotherapy with R-CHOP, and the pleural effusion disappeared. MALT lymphoma arising in the pleura is very rare, with only 12 published cases, and most cases have been described in Japan. CA125 levels correlated with the stage, tumor bulk, and presence of effusion. This patient exhibited a high level of CA125 that decreased with therapy.
authors.affiliation: Department of Hematology, Juntendo University Shizuoka Hospital.
authors.forename: Atsuko
authors.initials: A
authors.lastname: Yamada
authors.forename: Keiji
authors.initials: K
authors.lastname: Sugimoto
authors.forename: Kei
authors.initials: K
authors.lastname: Matuno
authors.forename: Miyuki
authors.initials: M
authors.lastname: Tutui
authors.forename: Yuriko
authors.initials: Y
authors.lastname: Yahata
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Tsukune
authors.forename: Michiaki
authors.initials: M
authors.lastname: Koike
authors.forename: Norio
authors.initials: N
authors.lastname: Komatsu
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis; D018394:CA-125 Antigen / Q000032:analysis; D003520:Cyclophosphamide / Q000008:administration & dosage; D003937:Diagnosis, Differential; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D008565:Membrane Proteins / Q000032:analysis; D010996:Pleural Effusion / Q000188:drug therapy / Q000209:etiology; D010997:Pleural Neoplasms / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D011241:Prednisone / Q000008:administration & dosage; D000069283:Rituximab; D014057:Tomography, X-Ray Computed; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; C451759:MUC16 protein, human; D008565:Membrane Proteins; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone